Altimmune, Inc. (ALT) SEC Filings & Earnings Calls

Increasing net loss and R&D spend without revenue

“Net loss increased to $22.8M from $22.1M; R&D expenses up 8.7%”

Clinical trial failure risk

“We have not generated any revenues from the sale of any products to date and there is no assurance of any future revenues from product sales.” · word for word

Dilution risk from warrants

“If all of the common stock warrants sold in the April 2026 Offering were to be exercised in cash at their exercise price, we would receive additional gross proceeds of $225 million.” · word for word

Clinical trial risk: Phase 2 results may not replicate in Phase 3; FDA meeting outcome uncertain.

“The Company plans to request an End-of-Phase 2 meeting with the FDA based on the results of the trial.” · word for word

No revenue or profitability; company is pre-commercial.

“Altimmune is a late clinical-stage biopharmaceutical company” · word for word

Relocation execution risk; potential disruption.

“plans to relocate its corporate headquarters” · word for word

Tariff and Inflation Risk

“If the tariffs and counter tariffs continue or escalate, they could have a significant negative effect on the global economy or on our operations, including continued inflationary pressures on raw materials, supply chain and logistics disruptions, and volatility in the capital markets, foreign exchange rates and interest rates.” · word for word

Middle East Conflict Risk

“Should the conflict continue or escalate, it could have a significant negative effect on the global economy or on our operations, including continued inflationary pressures on raw materials, oil and energy prices and clinical trial costs, supply chain and logistics disruptions, volatility in foreign exchange rates and interest rates and heightened cybersecur” · word for word

Clinical Trial Risk

“We have not generated any revenues from the sale of any products to date, and there is no assurance of any future revenues from product sales.” · word for word

Financing Risk

“In order to address our capital needs, including our planned clinical trials, we must continue to actively pursue additional equity or debt financing, and monetization of our existing programs through partnership arrangements or sales to third parties.” · word for word

No material risk signals; pre-revenue biotech with clinical trial execution risk.

Significant dilution from offering; warrants could further dilute if exercised.

“64,250,000 shares ... and ... pre-funded warrants ... to purchase up to 10,750,000 shares”

Clinical trial risk: Phase 3 MASH trial may fail, rendering capital deployment unsuccessful.

“to continue to advance the clinical development of pemvidutide, including funding and preparation for its global pivotal Phase 3 trial in MASH” · word for word

Clinical trial failure risk

“The Company is a clinical-stage biopharmaceutical company with no approved products and a history of net losses. Pemvidutide is in Phase 2/3 and may fail to meet endpoints or gain regulatory approval.”

Capital needs risk

“The Company is seeking to increase authorized shares from 200M to 400M to facilitate future capital raises, indicating ongoing dilution risk.”

No product revenue and history of losses

“We have not generated any revenue from the sale of any products to date. We have incurred significant losses since we commenced operations. As of December 31, 2025, we had an accumulated deficit of $649.5 million.” · word for word

Dependence on future capital raises

“In order to address our capital needs, including our planned clinical trials, we must continue to actively pursue additional equity or debt financing, and monetization of our existing programs through partnership arrangements or sales to third parties.” · word for word

Clinical trial execution risk

“The successful development of our product candidates is highly uncertain and may never result in approved products.” · word for word

Regulatory approval risk

“if the FDA, or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development of a product candidate, we could be required to expend significant additional financial resources and time on the completion of clinical development.” · word for word

Clinical trial risk; no approved products or revenue

“Pre-revenue biotech; Phase 3 MASH trial not yet initiated; AUD trial data expected Q3 2026”

Dilution risk from pre-funded warrants; no specific financial terms disclosed in this filing.

“Pre-Funded Warrant exhibit indicates potential future equity dilution.”

Clinical trial risk; Phase 3 may not replicate results.

“Forward-looking statements caution about risks and uncertainties.”

Clinical and regulatory risks for pemvidutide; CEO transition execution risk.

“risks relating to: delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy; the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company's produ” · word for word

Tariff and trade policy risk

“If the tariffs and counter tariffs continue or escalate, they could have a significant negative effect on the global economy or on our operations, including continued inflationary pressures on raw materials, supply chain and logistics disruptions, and volatility in the capital markets, foreign exchange rates and interest rates.” · word for word

Government shutdown risk

“If the shutdown continues for a prolonged period of time, it could result in significant delays in the SEC’s and FDA's ability to timely review and process any submissions we have filed or may file or cause other regulatory delays, which could have a material adverse effect on our business.” · word for word

Clinical trial failure risk

“We have not generated any revenues from the sale of any products to date and there is no assurance of any future revenues from product sales.” · word for word

Debt service obligations and milestone-dependent funding

“Loan bears interest at 9.70% or prime+2.45%; third and fourth tranches subject to milestone achievement and lender approval.”

Dilution risk from potential share sales

“Up to $200M in shares may be sold, increasing share count.”